DIP
NTLA icon

DT Investment Partners’s Intellia Therapeutics NTLA Stock Holding History

DT Investment Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$129 Hold
10
– – ﹤0.01% 514
2025
Q4 		$90 Hold
10
– – ﹤0.01% 540
2025
Q3 		$173 Hold
10
– – ﹤0.01% 529
2025
Q2 		$94 Hold
10
– – ﹤0.01% 527
2025
Q1 		$72 Hold
10
– – ﹤0.01% 547
2024
Q4 		$117 Hold
10
– – ﹤0.01% 549
2024
Q3 		$206 Buy
+10
New +$231 ﹤0.01% 622

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DT Investment Partners's NTLA Position: Q1 2026 in Review

DT Investment Partners held its Intellia Therapeutics (NTLA) position steady in Q1 2026 at 10 shares worth $129. The position accounts for ﹤0.01% of the portfolio, ranked #514.

DT Investment Partners first reported a position in NTLA in Q3 2024 and has held it in 7 quarters since. The position peaked at $206 in Q3 2024. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • DT Investment Partners held 10 shares of Intellia Therapeutics worth $129 as of Q1 2026.
  • DT Investment Partners left its Intellia Therapeutics share count unchanged in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of DT Investment Partners's portfolio in Q1 2026, its #514 holding.
  • DT Investment Partners first reported a position in Intellia Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • DT Investment Partners's Intellia Therapeutics position peaked at $206 in Q3 2024.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on DT Investment Partners's 13F filing for Q1 2026, filed 15 May 2026.